INTERLEUKIN GENETICS TO PRESENT AT G-2 REPORTS’ MOLECULAR DIAGNOSTIC CONFERENCE
02/02/2009
INTERLEUKIN GENETICS TO PRESENT AT G-2 REPORTS’ MOLECULAR DIAGNOSTIC CONFERENCE
CEO Lewis Bender Shares Vision for Genetic Testing Industry
Waltham, MA – February 2, 2009 – Interleukin Genetics, Inc. (NYSE Alternext US: ILI) announced today that Chief Executive Officer Lewis H. Bender will speak at the Washington G-2 Reports’ Business & Financial Strategies for Molecular Diagnostics conference, taking place February 2-4, 2009 in Fort Lauderdale, FL. The presentation is scheduled for Wednesday, February 4 at 8:30 a.m.
As part of his discussion, Mr. Bender will address the opportunities and challenges that exist within the genetic personalized health industry. The presentation will center on navigating genetic tests through consumer and physician channels from a regulatory, scientific and marketing standpoint, while providing a case study example to demonstrate their medical utility.
“The benefits of genetic testing across channels are significant,” said Bender. “Not only can drug developers improve their probability of success in clinical trials by using genetic biomarkers to screen out non-responders, but consumers can use genetic tests to improve wellness by personalizing their diet, environment and lifestyle choices best suited for their genetic makeup.”
Washington G-2 Reports’ Molecular Diagnostics conference will provide expert insight and advice on how laboratories can and are successfully integrating molecular diagnostics into their business strategies, given the current regulatory business environment.
About Interleukin Genetics
Interleukin Genetics, Inc. (NYSE: Alternext US: ILI), is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit http://www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
# # #
Contacts:
Erin Walsh
Interleukin Genetics, Inc.
781-419-4707
ewalsh@ilgenetics.com